At January 13, 2026, Dr. Chai Yan officially Joined Qurgen/Fuent (Qurgen’s primary China subsidiary) as Senior Vice President of Business Development of Qurgen, and the CEO of Suzhou Fuent Pharmaceutics. Also, he serves the Board Secretary to Accelerate the Company’s Strategic Advancement.
As the company enters the clinical stage, it requires not only scientific breakthroughs in pioneering new technologies but also demands strategic upgrade and robust execution. Dr. Chai will lead the company’s strategic transformation and be responsible for business development, financing management, and the overall operations of Fuent Pharmaceutics. His extensive experience in corporate management and capital markets provide strong support for achieving the key corporate milestones and accelerating the company’s strategic advancement.
Dr. Chai holds a master’s degree in international business management from the University of Nottingham (UK) and a Doctor of Business Administration (DBA) from Arizona State University (USA). Prior to joining Qurgen/Fuent, Dr.Chai served as Senior Operating Officer at IQVIA, where he was responsible for strategic and commercialization consulting for biopharmaceutical companies, commercial outsourcing services, market access, public policy, and government affairs. Earlier in his career, Dr. Chai held analytical and investment roles at McKinsey & Company and Harvard University Alumni Endowment Foundation.
“I am honored to join Qurgen/Fuent at this pivotal stage of the company’s development,” said Dr. Chai. “Qurgen/Fuent has a solid scientific foundation, a clear clinical development pathway, and an exceptional team spanning clinical operations, innovative technology development, and drug manufacturing. Our mission is not only to demonstrate scientifically the value of our novel protein therapeutics, but also to communicate our groundbreaking potential in the capital markets. As a member of the management team, I will work closely with my colleagues to accelerate the company’s growth, improve operational efficiency, ensure resources are allocated to the high-value pipelines, and ultimately bring innovative treatment solutions to patients at soon as possible.”
